Literature DB >> 7715479

Compliance to hormone replacement therapy in menopausal women controlled in a third level academic centre.

A Cano1.   

Abstract

Compliance to distinct combinations of hormone replacement therapy was assessed in 331 postmenopausal women treated for 1 to 5 years in the Menopause Unit of a third level referral Academic Hospital. Forty nine women (15%) had interrupted therapy, mainly during the first year, while 29 (9%) never had their prescriptions filled. Forty five women (14%) followed the treatment intermittently or only sporadically completed the treatment as prescribed. Four main factors were analyzed for their eventual influence on compliance: the inclusion of progestins in the prescription, the source of referral, the severity of menopause-induced symptomatology, and the route of estrogen administration. The source of referral divided women into three groups: patients referred from a doctor, those addressed from the gynecology ward of the hospital, and women who directly asked to be taken as patients in the unit. The intensity of clinical manifestations was assessed through the Kupperman index. Only two variables, the addition of progestins (P < 0.02), and the oral route of estrogen administration (P < 0.01) determined lower levels of compliance. The other two factors did not induce significant changes in the attitude of the patients towards hormone therapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7715479     DOI: 10.1016/0378-5122(94)90004-3

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  7 in total

1.  Biochemical markers of bone turnover part II: clinical applications in the management of osteoporosis.

Authors:  Markus J Seibel
Journal:  Clin Biochem Rev       Date:  2006-08

2.  Prevalence and duration of postmenopausal hormone replacement therapy use in a managed care organization, 1990-1995.

Authors:  M T Connelly; M Richardson; R Platt
Journal:  J Gen Intern Med       Date:  2000-08       Impact factor: 5.128

3.  Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database.

Authors:  Alexandra Papaioannou; George Ioannidis; Jonathan D Adachi; Rolf J Sebaldt; Nicole Ferko; Mark Puglia; Jacques Brown; Alan Tenenhouse; Wojciech P Olszynski; Pauline Boulos; David A Hanley; Robert Josse; Timothy M Murray; Annie Petrie; Charlie H Goldsmith
Journal:  Osteoporos Int       Date:  2003-09-11       Impact factor: 4.507

4.  Persistence with teriparatide in patients with osteoporosis: the UK experience.

Authors:  N K Arden; S Earl; D J Fisher; C Cooper; S Carruthers; M Goater
Journal:  Osteoporos Int       Date:  2006-07-06       Impact factor: 4.507

5.  Ovarian survival after pelvic radiation: transposition until the age of 35 years.

Authors:  Ellen J Hoekman; Dan Knoester; Alexander A W Peters; Frank W Jansen; Cornelis D de Kroon; Carina G J M Hilders
Journal:  Arch Gynecol Obstet       Date:  2018-09-14       Impact factor: 2.344

6.  Transdermal hormone therapy in postmenopausal women: a review of metabolic effects and drug delivery technologies.

Authors:  Nathan W Kopper; Jennifer Gudeman; Daniel J Thompson
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

7.  Impact of multidisciplinary collaborative pharmaceutical care on knowledge, adherence, and efficacy of hormone therapy in climacteric women.

Authors:  Min Lu; Ying Zhou; BaoJing Wang; ZheWen Hu; Ying Du; ShiFang Liu; XiuFeng Lin; YiMin Cui; HongYan Jin
Journal:  Patient Prefer Adherence       Date:  2018-07-19       Impact factor: 2.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.